| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Nonadecanoic acid does not have a single defined pharmacological target. As a 19-carbon saturated fatty acid found in fats and vegetable oils, it may interact with various cellular processes involved in lipid metabolism, membrane structure, and cell signaling. The compound has been shown to inhibit HL-60 cancer cell proliferation with an IC₅₀ value of 68 μM. Fatty acids can modulate cell proliferation through effects on membrane fluidity, lipid raft composition, and signaling pathways such as PPARs (peroxisome proliferator-activated receptors) and NF-κB. Nonadecanoic acid may also serve as a substrate for fatty acid metabolism enzymes or as a component of cellular membranes. Further research is needed to identify its specific molecular targets.
|
|---|---|
| ln Vitro |
In vitro, Nonadecanoic acid has been shown to inhibit HL-60 cancer cell proliferation with an IC₅₀ value of 68 μM. The compound is a 19-carbon saturated fatty acid found in fats and vegetable oils. Its anti-proliferative activity suggests potential applications in cancer research. The compound may exert its effects through modulation of lipid metabolism, membrane structure, or cell signaling pathways. Nonadecanoic acid serves as a biochemical tool for studying fatty acid metabolism and cancer cell biology. Its in vitro activity is concentration-dependent, with efficacy observed at micromolar concentrations. The compound's effects on other cancer cell lines or normal cells require further investigation.
|
| ln Vivo |
In vivo data for Nonadecanoic acid are limited as the compound is primarily used as a research chemical. As a naturally occurring saturated fatty acid found in fats and vegetable oils, it is metabolized through normal fatty acid oxidation pathways. The compound's anti-proliferative activity against HL-60 cancer cells suggests potential for in vivo studies in cancer models. However, detailed in vivo efficacy, pharmacokinetic, and toxicological data for Nonadecanoic acid require further investigation from primary research publications. The compound is intended for research use only and is not approved for therapeutic applications.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cellular) assays for Nonadecanoic acid are not standard pharmacological assays. However, the compound may be studied for its interactions with fatty acid binding proteins, PPARs, or other lipid-binding proteins. Binding assays using radiolabeled or fluorescently labeled fatty acids can measure displacement by Nonadecanoic acid. Enzyme activity assays for fatty acid metabolizing enzymes (e.g., acyl-CoA synthetase, fatty acid desaturase) may use Nonadecanoic acid as a substrate or inhibitor. The compound's anti-proliferative activity may also be assessed using cell-free assays measuring effects on signaling pathways or enzyme activities. These assays help characterize the compound's biochemical properties and potential mechanisms of action.
|
| Cell Assay |
In vitro cellular experiments with Nonadecanoic acid are performed using HL-60 leukemia cells to assess its anti-proliferative activity. Cells are cultured in appropriate media (e.g., RPMI 1640 with 10% FBS) and treated with varying concentrations of Nonadecanoic acid (typically 10-200 μM) for 24-72 hours. Cell viability and proliferation are assessed using MTT, CellTiter-Glo, or trypan blue exclusion assays. The IC₅₀ of 68 μM is determined from concentration-response curves. Apoptosis may be evaluated by Annexin V/PI staining and flow cytometry. Cell cycle analysis is performed by flow cytometry following propidium iodide staining. The compound's effects on lipid metabolism and signaling pathways may be assessed by Western blot or biochemical assays. Cells are maintained at 37°C in 5% CO₂ with appropriate media supplements.
|
| Animal Protocol |
In vivo animal studies with Nonadecanoic acid have not been extensively reported. As a naturally occurring saturated fatty acid found in fats and vegetable oils, it is a normal component of the diet and is metabolized through fatty acid oxidation pathways. For cancer research, standard in vivo models could include xenografts of HL-60 or other leukemia cell lines. Animals would be treated with Nonadecanoic acid via oral or intraperitoneal administration, and efficacy assessed by measuring tumor growth, survival, and hematological parameters. However, detailed in vivo studies are needed to establish its therapeutic potential. The compound is intended for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Nonadecanoic acid are not extensively characterized. The compound has molecular formula C₁₉H₃₈O₂ and molecular weight 298.5 g/mol. It appears as white flakes or powder with a melting point of 68-70°C. Boiling point is 297°C at 100 mmHg. Density is 0.886±0.06 g/cm³ (predicted). The pKa is 4.78±0.10 (predicted). LogP is estimated at 8.339, indicating high lipophilicity. Storage: 2-8°C. As a long-chain saturated fatty acid (C19:0), it is expected to be absorbed through dietary fat absorption pathways, incorporated into lipoproteins, and metabolized by β-oxidation. Detailed pharmacokinetic parameters require further investigation.
|
| Toxicity/Toxicokinetics |
Toxicological information for Nonadecanoic acid indicates hazard code Xi (Irritant). Risk statements include R36/37/38 (Irritating to eyes, respiratory system, and skin). Safety statements include S26 (In case of contact with eyes, rinse immediately with plenty of water and seek medical advice). The compound is classified as a combustible solid (Storage Class 11) and is stable but incompatible with bases, reducing agents, and oxidizing agents. Standard safety precautions for handling research chemicals apply, including use of personal protective equipment (gloves, safety goggles, lab coat) and working in a well-ventilated area. The compound is for research use only.
|
| References | |
| Additional Infomation |
Nonadecanoic acid (NCO) is a C19 straight-chain fatty acid derived from plants or bacteria. It is an intermediate in the biodegradation of n-eicosane and has been shown to inhibit cancer cell growth. It is also a fungal metabolite. NCO is both a straight-chain saturated fatty acid and a long-chain fatty acid. It is the conjugate acid of NCO. It has been reported that NCO is found in potatoes (Solanum tuberosum), Streptomyces, and several other organisms with relevant data. See also: Fatty Acids, C16-22 (Note moved here).
Nonadecanoic acid (CAS 646-30-0) is a 19-carbon saturated fatty acid found in fats and vegetable oils. The compound has molecular formula C₁₉H₃₈O₂ and molecular weight 298.5 g/mol. It appears as white flakes or powder with a melting point of 68-70°C. Nonadecanoic acid is also known as n-nonadecanoic acid, C19:0 fatty acid, and nonadecyclic acid. It has been shown to inhibit HL-60 cancer cell proliferation with an IC₅₀ value of 68 μM. Purity: ≥98%. Storage: 2-8°C. |
| Molecular Formula |
C19H38O2
|
|---|---|
| Molecular Weight |
298.5038
|
| Exact Mass |
298.287
|
| CAS # |
646-30-0
|
| Related CAS # |
Nonadecanoic acid-d37;1219798-49-8
|
| PubChem CID |
12591
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
368.1±5.0 °C at 760 mmHg
|
| Melting Point |
68-70 °C(lit.)
|
| Flash Point |
166.1±12.5 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.457
|
| LogP |
8.75
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
21
|
| Complexity |
214
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ISYWECDDZWTKFF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H38O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19(20)21/h2-18H2,1H3,(H,20,21)
|
| Chemical Name |
nonadecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~335.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3501 mL | 16.7504 mL | 33.5008 mL | |
| 5 mM | 0.6700 mL | 3.3501 mL | 6.7002 mL | |
| 10 mM | 0.3350 mL | 1.6750 mL | 3.3501 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA